CLINICAL_TRIALS
trial_result
· 2026-04-03
Clinical Trial Update: Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies [Phase 2]
Summary
Phase 2 trial evaluating safety, tolerability, pharmacokinetics, and biomarker changes with nilotinib in patients with Dementia with Lewy bodies.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Georgetown University | Conditions: Dementia With Lewy Bodies | Phase 2 | Status: COMPLETED | Results posted: 2026-04-03